It is in Lugano, Switzerland, that the ESMO, the European high mass of oncology, ends this Tuesday.
Some 25,000 participants from academic research and the pharmaceutical industry participated virtually in the congress, with 2,000 presentations around the latest therapeutic advances.
Oncology remains the first market for the pharmaceutical industry: it generated last year 163 billion dollars in turnover (out of 613 billion in total), up 11.9%, according to GlobalData.
Over the last twenty years, it has posted an average annual growth of 15.4%.
"It is the main driving force
behind
the market because there is still a lot to be invented in the face of significant unmet medical needs,"
explains Jean-Jacques Le Fur, specialist in the sector at Bryan, Garnier & Co.
Conversely, certain markets such as asthma or psoriasis begin to be saturated.
For the players, the barrier to entry is technological, with the discovery of new mechanisms every day.
This article is for subscribers only.
You have 76% left to discover.
To cultivate one's freedom is to cultivate one's curiosity.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
